VivoSim receives $5 million Lilly milestone
VivoSim Labs (NASDAQ:VIVS) received $5 million from Eli Lilly (NYSE:LLY) after first Phase 2 dosing and could earn another $45 million.
VivoSim Labs (NASDAQ:VIVS) received $5 million from Eli Lilly (NYSE:LLY) after first Phase 2 dosing and could earn another $45 million.
Community Trust Bancorp (NASDAQ:CTBI) reported record Q2 2026 net income of $29.6 million and basic earnings of $1.64 per share.
Eos Energy Enterprises (NASDAQ:EOSE) expects record Q2 revenue of $68–$69 million as shipments more than tripled year over year.
Intensity Therapeutics (NASDAQ:INTS) restarted dosing in its 61-patient INVINCIBLE-4 trial, testing INT230-6 before standard treatment for presurgical TNBC.
Halliburton (NYSE:HAL) announced it secured a multi-year contract from Aramco to support unconventional gas development programs in Saudi Arabia.
Morgan Stanley's stock traders beat expectations to set another quarterly record as the firm earned $6.3 billion from equity trading in the period, a 69% jump that topped its previous all-time high from the first quarter. Jonathan Ferro and Lisa Abramowicz examine the results on "Bloomberg Surveillance."
Sify Technologies (NASDAQ:SIFY) reported Q1 FY2026-27 revenue of ₹12.352 billion, up 15%, with a ₹65 million profit.
Kaspi.kz (NASDAQ:KSPI) announced it completed the acquisition of Rabobank A.Ş. to expand its digital banking operations for its regional network of 25 million consumers.
Conagra Brands (NYSE:CAG) reported Q4 fiscal 2026 net sales of $2.9 billion, a diluted loss of $3.37 per share and an annualized dividend cut to $0.70.
Morgan Stanley (NYSE:MS) reported record Q2 2026 net revenue of $21.3 billion and diluted EPS of $3.46 as its major business divisions expanded.
Bruker (NASDAQ:BRKR) acquired DISQVER, an mNGS platform that can analyze blood-derived cell-free DNA for more than 11,000 microbes within 24 hours.
Axsome Therapeutics (NASDAQ:AXSM) announced the FDA accepted its New Drug Application for narcolepsy treatment AXS-12, setting a 2027 target date.